U.S. markets close in 2 hours 19 minutes

Merck KGaA (MRK.DE)

XETRA - XETRA Delayed Price. Currency in EUR
158.90-1.25 (-0.78%)
At close: 05:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close160.15
Bid158.95 x 6700
Ask159.05 x 11200
Day's Range157.90 - 160.20
52 Week Range135.00 - 202.80
Avg. Volume320,225
Market Cap69.086B
Beta (5Y Monthly)0.67
PE Ratio (TTM)23.86
EPS (TTM)6.66
Earnings DateNov 09, 2023
Forward Dividend & Yield2.20 (1.37%)
Ex-Dividend DateMay 02, 2023
1y Target Est187.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MRK.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Simply Wall St.

      Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 85% Above Its Share Price

      Key Insights The projected fair value for Merck KGaA is €297 based on 2 Stage Free Cash Flow to Equity Current share...

    • Thomson Reuters StreetEvents

      Q3 2023 Exscientia PLC Earnings Call

      Q3 2023 Exscientia PLC Earnings Call

    • Reuters

      Merck KGaA says FY profit to fall to lower half of target range

      FRANKFURT (Reuters) -Germany's diversified group Merck KGaA flagged that full-year operating earnings would likely be in the lower half of its target range on weak demand for specialty materials that are used to make biotech drugs and semiconductors. The maker of pharmaceuticals, lab gear and specialty chemicals confirmed that 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, would come in between 5.8 billion euros ($6.21 billion) and 6.4 billion euros but would be "trending in the lower half of the absolute range". Last month, Merck raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.